Lauren C J Baker Selected Research

bisbenzimide ethoxide trihydrochloride (Hoechst 33342)

1/2018	Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.
8/2017	Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.
10/2012	Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
7/2011	Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lauren C J Baker Research Topics

Disease

8	Neoplasms (Cancer) 01/2018 - 07/2011
3	Hypoxia (Hypoxemia) 08/2017 - 10/2012
2	Squamous Cell Carcinoma of Head and Neck 01/2018 - 08/2017
2	Prolactinoma (Prolactinomas) 09/2013 - 08/2013
1	Hyperoxia 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 10/2016
1	Colonic Neoplasms (Colon Cancer) 01/2016
1	Neuroblastoma 01/2013
1	Vascular Remodeling 10/2012
1	Glioma (Gliomas) 10/2012
1	Necrosis 10/2012
1	Colorectal Neoplasms (Colorectal Cancer) 07/2011

Drug/Important Bio-Agent (IBA)

7	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2011
5	carbogenIBA 10/2016 - 07/2011
4	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 01/2018 - 07/2011
4	pimonidazoleIBA 01/2018 - 10/2012
3	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 10/2016 - 07/2011
2	Pharmaceutical PreparationsIBA 01/2018 - 10/2016
2	Oxygen (Dioxygen)IBA 01/2018 - 08/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 10/2012
2	cediranib (AZD2171)IBA 01/2013 - 10/2012
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	deoxyhemoglobinIBA 08/2017
1	vanucizumabIBA 01/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	Omalizumab (Xolair)FDA Link 01/2016
1	Immunoglobulin E (IgE)IBA 01/2016
1	CCI 103FIBA 09/2013
1	azomycinIBA 09/2013
1	Hemoglobins (Hemoglobin)IBA 08/2013
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013
1	N-acetylcochinol-O-phosphateIBA 01/2013
1	Angiogenesis InhibitorsIBA 01/2013

Therapy/Procedure

4	Therapeutics 01/2018 - 10/2012
3	Aftercare (After-Treatment) 01/2016 - 10/2012
2	Intravenous Administration 10/2016 - 07/2011